FindTrial
Sign In

XL184

DRUG6 trials

Sponsors

Exelixis

Conditions

CancerCarcinoma, Non-Small-Cell LungFollicular Thyroid CancerGiant Cell GlioblastomaGlioblastomaGlioblastoma MultiformeGliosarcomaHuerthle Cell Thyroid Cancer

Phase 1

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
CompletedNCT00215605
ExelixisCancer, Lymphoma, Thyroid Carcinoma
Start: 2005-09-30End: 2012-07-31Updated: 2013-02-27
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
CompletedNCT00596648
ExelixisCarcinoma, Non-Small-Cell Lung
Start: 2008-02-12End: 2012-08-02Updated: 2026-01-13
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
CompletedNCT00960492
ExelixisGiant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Start: 2009-09-30End: 2013-10-31Updated: 2014-09-22
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
CompletedNCT01100619
ExelixisFollicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Papillary Thyroid Cancer +1
Start: 2010-04-30Updated: 2013-09-19

Phase 2

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
CompletedNCT00704288
ExelixisGlioblastoma Multiforme
Start: 2008-05-31End: 2012-12-31Updated: 2024-02-05

Phase 3

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
CompletedNCT00704730
ExelixisThyroid Cancer
Start: 2008-06-30End: 2020-09-30Updated: 2021-04-20

Related Papers

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
Clinical Cancer Research2023-08-047 citations
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.
Journal of Clinical Oncology2023-06-011 citations
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
Neuro-Oncology Advances2021-01-013 citations
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma.
2020-05-2012 citations
Unexpected Success for a TKI in Activating Anticancer Innate Immunity
Oncology Times2018-10-30
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
2018-09-0128 citations
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
2017-11-01158 citations
NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE
Neuro-Oncology2017-11-01
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
Neuro-Oncology2017-08-1570 citations
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Neuro-Oncology2017-08-11112 citations
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials
Clinical Cancer Research2017-06-2863 citations
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
2017-03-2830 citations
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
2016-08-3168 citations
Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.
Journal of Clinical Oncology2015-05-2034 citations
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
2014-05-14122 citations
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
2013-05-1426 citations
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
2011-05-23419 citations